Loading…
Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis
Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent...
Saved in:
| Published in: | PloS one 2015-04, Vol.10 (4), p.e0124021-e0124021 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3 |
| container_end_page | e0124021 |
| container_issue | 4 |
| container_start_page | e0124021 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Liu, Jichen Li, Menghao Lu, Hao Qiao, Weiguang Xi, Dan Luo, TianTian Xiong, Haowei Guo, Zhigang |
| description | Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis.
Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI.
Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P |
| doi_str_mv | 10.1371/journal.pone.0124021 |
| format | article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1674683647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A422736268</galeid><doaj_id>oai_doaj_org_article_da59acbf824e4bad8286619b04a2c0aa</doaj_id><sourcerecordid>A422736268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYqPwDxBYQkJw0ZL4O7tAmqYBlSZN4uvWOnHs1lMSd3ZS6L_HpdnUoF2gXDiyn_e1z2ufLHtZ5IuCiOLDjR9CB81i4zuzyAtMc1w8yk6LkuA5xzl5fPR_kj2L8SbPGZGcP81OMJOlJAKfZreX1hrdR-Qt2gRfDdo3yHcomNibzkcXEdjeBLQxQQ89dMYPEWkffAdhh1yX1ram653vzhCguEuyFnqnk8PWmV8Iuhq1poc5pMPukt_z7ImFJpoX4zjLfny6_H7xZX51_Xl5cX4114LJfk6lxJwwCiwvJcUgqOCFZMxWTDNS2aoAsEJUnBBaklxzRuuSSG1rLqraGDLLXh98N42PakwrqoILyiXhVCRieSBqDzdqE1ybSlIenPo74cNKQUilNEbVwErQlZWYGlpBLXEKsiirnALWOUDy-jjuNlStqXWKJEAzMZ2udG6tVn6rKE23wngyeDcaBH87pPRV66I2TXOIfH9uJnkpKEvom3_Qh6sbqRWkAlxnfdpX703VOcVYEI4TOcsWD1Dpq03rdHpa1qX5ieD9RJCY3vzuVzDEqJbfvv4_e_1zyr49YtcGmn4dfTPsX1acgvQA6uBjDMbeh1zkat8Zd2mofWeosTOS7NXxBd2L7lqB_AF6YAqu</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674683647</pqid></control><display><type>article</type><title>Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Liu, Jichen ; Li, Menghao ; Lu, Hao ; Qiao, Weiguang ; Xi, Dan ; Luo, TianTian ; Xiong, Haowei ; Guo, Zhigang</creator><contributor>Benedetto, Umberto</contributor><creatorcontrib>Liu, Jichen ; Li, Menghao ; Lu, Hao ; Qiao, Weiguang ; Xi, Dan ; Luo, TianTian ; Xiong, Haowei ; Guo, Zhigang ; Benedetto, Umberto</creatorcontrib><description>Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis.
Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI.
Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P<0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01).
Probucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0124021</identifier><identifier>PMID: 25898372</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Angiography ; Angioplasty ; Anticholesteremic Agents - pharmacology ; Anticholesteremic Agents - therapeutic use ; Balloon angioplasty ; Blood vessels ; Cardiovascular Agents - pharmacology ; Cardiovascular Agents - therapeutic use ; Clinical trials ; Combined Modality Therapy ; Coronary Disease - therapy ; Humans ; Implantation ; Implants ; Incidence ; Intervention ; Lipids ; Medical research ; Meta-analysis ; Patients ; Percutaneous Coronary Intervention ; Probucol ; Probucol - pharmacology ; Probucol - therapeutic use ; Restenosis ; Risk reduction ; Stenosis ; Stents ; Studies ; Surgical implants ; Treatment Outcome</subject><ispartof>PloS one, 2015-04, Vol.10 (4), p.e0124021-e0124021</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Liu et al 2015 Liu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3</citedby><cites>FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1674683647/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1674683647?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,25736,27907,27908,36995,36996,44573,53774,53776,74877</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25898372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Benedetto, Umberto</contributor><creatorcontrib>Liu, Jichen</creatorcontrib><creatorcontrib>Li, Menghao</creatorcontrib><creatorcontrib>Lu, Hao</creatorcontrib><creatorcontrib>Qiao, Weiguang</creatorcontrib><creatorcontrib>Xi, Dan</creatorcontrib><creatorcontrib>Luo, TianTian</creatorcontrib><creatorcontrib>Xiong, Haowei</creatorcontrib><creatorcontrib>Guo, Zhigang</creatorcontrib><title>Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis.
Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI.
Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P<0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01).
Probucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI.</description><subject>Analysis</subject><subject>Angiography</subject><subject>Angioplasty</subject><subject>Anticholesteremic Agents - pharmacology</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Balloon angioplasty</subject><subject>Blood vessels</subject><subject>Cardiovascular Agents - pharmacology</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Coronary Disease - therapy</subject><subject>Humans</subject><subject>Implantation</subject><subject>Implants</subject><subject>Incidence</subject><subject>Intervention</subject><subject>Lipids</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Patients</subject><subject>Percutaneous Coronary Intervention</subject><subject>Probucol</subject><subject>Probucol - pharmacology</subject><subject>Probucol - therapeutic use</subject><subject>Restenosis</subject><subject>Risk reduction</subject><subject>Stenosis</subject><subject>Stents</subject><subject>Studies</subject><subject>Surgical implants</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYqPwDxBYQkJw0ZL4O7tAmqYBlSZN4uvWOnHs1lMSd3ZS6L_HpdnUoF2gXDiyn_e1z2ufLHtZ5IuCiOLDjR9CB81i4zuzyAtMc1w8yk6LkuA5xzl5fPR_kj2L8SbPGZGcP81OMJOlJAKfZreX1hrdR-Qt2gRfDdo3yHcomNibzkcXEdjeBLQxQQ89dMYPEWkffAdhh1yX1ram653vzhCguEuyFnqnk8PWmV8Iuhq1poc5pMPukt_z7ImFJpoX4zjLfny6_H7xZX51_Xl5cX4114LJfk6lxJwwCiwvJcUgqOCFZMxWTDNS2aoAsEJUnBBaklxzRuuSSG1rLqraGDLLXh98N42PakwrqoILyiXhVCRieSBqDzdqE1ybSlIenPo74cNKQUilNEbVwErQlZWYGlpBLXEKsiirnALWOUDy-jjuNlStqXWKJEAzMZ2udG6tVn6rKE23wngyeDcaBH87pPRV66I2TXOIfH9uJnkpKEvom3_Qh6sbqRWkAlxnfdpX703VOcVYEI4TOcsWD1Dpq03rdHpa1qX5ieD9RJCY3vzuVzDEqJbfvv4_e_1zyr49YtcGmn4dfTPsX1acgvQA6uBjDMbeh1zkat8Zd2mofWeosTOS7NXxBd2L7lqB_AF6YAqu</recordid><startdate>20150421</startdate><enddate>20150421</enddate><creator>Liu, Jichen</creator><creator>Li, Menghao</creator><creator>Lu, Hao</creator><creator>Qiao, Weiguang</creator><creator>Xi, Dan</creator><creator>Luo, TianTian</creator><creator>Xiong, Haowei</creator><creator>Guo, Zhigang</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150421</creationdate><title>Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis</title><author>Liu, Jichen ; Li, Menghao ; Lu, Hao ; Qiao, Weiguang ; Xi, Dan ; Luo, TianTian ; Xiong, Haowei ; Guo, Zhigang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Angiography</topic><topic>Angioplasty</topic><topic>Anticholesteremic Agents - pharmacology</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Balloon angioplasty</topic><topic>Blood vessels</topic><topic>Cardiovascular Agents - pharmacology</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Coronary Disease - therapy</topic><topic>Humans</topic><topic>Implantation</topic><topic>Implants</topic><topic>Incidence</topic><topic>Intervention</topic><topic>Lipids</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Patients</topic><topic>Percutaneous Coronary Intervention</topic><topic>Probucol</topic><topic>Probucol - pharmacology</topic><topic>Probucol - therapeutic use</topic><topic>Restenosis</topic><topic>Risk reduction</topic><topic>Stenosis</topic><topic>Stents</topic><topic>Studies</topic><topic>Surgical implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jichen</creatorcontrib><creatorcontrib>Li, Menghao</creatorcontrib><creatorcontrib>Lu, Hao</creatorcontrib><creatorcontrib>Qiao, Weiguang</creatorcontrib><creatorcontrib>Xi, Dan</creatorcontrib><creatorcontrib>Luo, TianTian</creatorcontrib><creatorcontrib>Xiong, Haowei</creatorcontrib><creatorcontrib>Guo, Zhigang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jichen</au><au>Li, Menghao</au><au>Lu, Hao</au><au>Qiao, Weiguang</au><au>Xi, Dan</au><au>Luo, TianTian</au><au>Xiong, Haowei</au><au>Guo, Zhigang</au><au>Benedetto, Umberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-04-21</date><risdate>2015</risdate><volume>10</volume><issue>4</issue><spage>e0124021</spage><epage>e0124021</epage><pages>e0124021-e0124021</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis.
Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI.
Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P<0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01).
Probucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25898372</pmid><doi>10.1371/journal.pone.0124021</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-04, Vol.10 (4), p.e0124021-e0124021 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1674683647 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Analysis Angiography Angioplasty Anticholesteremic Agents - pharmacology Anticholesteremic Agents - therapeutic use Balloon angioplasty Blood vessels Cardiovascular Agents - pharmacology Cardiovascular Agents - therapeutic use Clinical trials Combined Modality Therapy Coronary Disease - therapy Humans Implantation Implants Incidence Intervention Lipids Medical research Meta-analysis Patients Percutaneous Coronary Intervention Probucol Probucol - pharmacology Probucol - therapeutic use Restenosis Risk reduction Stenosis Stents Studies Surgical implants Treatment Outcome |
| title | Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A39%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20probucol%20on%20restenosis%20after%20percutaneous%20coronary%20intervention:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Liu,%20Jichen&rft.date=2015-04-21&rft.volume=10&rft.issue=4&rft.spage=e0124021&rft.epage=e0124021&rft.pages=e0124021-e0124021&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0124021&rft_dat=%3Cgale_plos_%3EA422736268%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c758t-48826354a509842a74761855fb5c53bfb1aaf77b6334930c654d938cfd67bdee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1674683647&rft_id=info:pmid/25898372&rft_galeid=A422736268&rfr_iscdi=true |